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Abstract
Background: CB1 cannabinoid receptors are G-protein coupled receptors for endocannabinoids
including anandamide and 2-arachidonoylglycerol. Because these arachidonic acid metabolites
possess a 20-carbon polyene chain as the alkyl terminal moiety, they are highly flexible with the
potential to adopt multiple biologically relevant conformations, particularly those in a bent form.
To better understand the molecular interactions associated with binding and steric trigger
mechanisms of receptor activation, a series of conformationally-restricted anandamide analogs
having a wide range of affinity and efficacy were evaluated.
Results: A CB1 receptor model was constructed to include the extracellular loops, particularly
extracellular loop 2 which possesses an internal disulfide linkage. Using both Glide (Schrödinger)
and Affinity (Accelrys) docking programs, binding conformations of six anandamide analogs were
identified that conform to rules applicable to the potent, efficacious and stereoselective non-
classical cannabinoid CP55244. Calculated binding energies of the optimum structures from both
procedures correlated well with the reported binding affinity values. The most potent and
efficacious of the ligands adopted conformations characterized by interactions with both the helix-
3 lysine and hydrophobic residues that interact with CP55244. The other five compounds formed
fewer or less energetically favorable interactions with these critical residues. The flexibility of the
tested anandamide analogs, measured by torsion angles around the benzene as well as the stretch
between side chain moieties, could contribute to the differences in ability to interact with the CB1
receptor.
Conclusion:  Analyses of multiple poses of conformationally-restricted anandamide analogs
permitted identification of favored amino acid interactions within the CB1 receptor binding pocket.
A ligand possessing both high affinity and cannabinoid agonist efficacy was able to interact with both
polar and hydrophobic interaction sites utilized by the potent and efficacious non-classical
cannabinoid CP55940. In contrast, other analogs characterized by reduced affinity or efficacy
exhibited less favorable interactions with those key residues.
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Background
CB1 and CB2 cannabinoid receptors belong to the G-pro-
tein coupled receptor (GPCR) family. Members of this
cell-surface receptor family are characterized by seven
transmembrane (TM) helices connected by intra- and
extracellular loops. Lipid ligands serve as the regulators of
these receptors, and are collectively referred to as endo-
cannabinoids. Anandamide (also known as N-arachido-
nylethanolamide) [1], 2-arachidonoylglycerol (2-AG)
[2,3], 2-arachidonyl glyceryl ether (2-AGE or nolandin
ether) [4], and virodhamine (arachidonyl ethanolamine
ester) [5] (Fig. 1) have been reported to be endocannabi-
noids. A common feature of endocannabinoids is the long
polyene hydrocarbon chain as the alkyl terminal moiety,
which makes these compounds highly flexible with the
potential to adopt many different binding conformations.
Investigation of the bioactive conformation of anandam-
ide can provide valuable insight into how endocannabi-
noids interact with the cannabinoid receptor and how
their binding transfers the molecular signal to the coupled
G-proteins. However, due to the conformational flexibil-
ity of anandamide, determination of the bioactive confor-
mation within the CB1  receptor active site has been
hampered. Although the binding mode of anandamide
within the receptor remains to be determined, it has been
demonstrated that anandamide is able to adopt quite dif-
ferent conformations in various media [6-8].
One theory for binding of ligands to the cannabinoid
receptor suggests that anandamide is in an extended con-
formation, with the ethanolamide head group near the
extracellular surface of the receptor and the long hydrocar-
bon chain extending down into the core of the membrane
[9]. Another possibility is that anandamide may exhibit a
binding mode similar to that demonstrated for arachi-
donic acid, its biological precursor. Arachidonic acid is
known to be a substrate for oxygenase enzymes such as
cyclooxygenases (COXs) and arachidonate 15-lipoxygen-
ase (15-LO). X-ray crystal structures of arachidonic acid in
a complex with these proteins revealed that arachidonic
acid formed many different bioactive conformations, as
shown in Fig. 2. Many X-ray structures for arachidonic
acid show a bent conformation when co-crystallized in
adipocyte lipid binding protein (PDB code: 1ADL),
cyclooxygenase COX-2 (PDB code: 1CVU), prostaglandin
H2 synthase-1 (PDB code: 1DIY), and fatty acid amide
hydrolase (FAAH) (PDB code: 1MT5). Modeling studies
of arachidonic acid in these proteins predict structures
that are also bent in conformation [10-12]. Thus, it is fair
to say that there may not be a single bioactive conforma-
tion of anandamide, but several multiple conformations
may exist, particularly those in a bent form.
For the purpose of gaining insight into the binding of
anandamide and its molecular interactions with the can-
nabinoid receptors, a series of conformationally-restricted
anandamide analogs was synthesized and pharmacologi-
cally characterized [13]. In these restricted structures, aro-
matic rings replaced the long, unsaturated alkyl chains,
based on a common pharmacophore model between
endocannabinoids and traditional cannabinoids [14].
This class of anandamide analogs was designed based
upon ligand-based modeling studies using constrained
molecular dynamics simulations. A 3-dimentional quan-
titative structure-activity relationship (3D-QSAR) model
was derived using constrained molecular field analysis
(CoMFA) for a training set of 29 classical and nonclassical
analogs, which rationalized the binding affinity in terms
of steric and electrostatic properties. More importantly,
this model predicted the potency of anandamide in excel-
lent agreement with experimental data. In GTPγS binding
assays to detect activation of G-proteins and adenylyl
cyclase assays to detect effector regulation via Gi, com-
pound 1 (Table 1) was quite comparable in affinity as well
as functional activity, whereas other compounds possess-
ing small structural changes were significantly different in
binding and/or activity [13].
In the present study, we report a docking study of com-
pounds 1 through 6 (Table 1), using an updated model of
the CB1 receptor in which the extracellular loops have
been incorporated. Binding conformations of these lig-
Structures of Endocannabinoids and CP55244 Figure 1
Structures of Endocannabinoids and CP55244. The 
structures of anandamide (N-arachidonylethanolamide), 2-
arachidonoylglycerol (2-AG), nolandin ether (2-arachidonyl 
glyeryl ether, 2-AGE), and virodhamine (arachidonyleth-
anolamine ester) are shown. The non-classical cannabinoid, 
CP55244 is depicted with the accepted numbering and ring 
nomenclature.
N
H
O
OH
O
O
OH
OH
O
OH
OH
O
O
NH2
OH
OH
HO
CP55244
A
C 1
3
5
D
2-arachidonoylglycerol N-arachidonylethanolamide
2-arachidonyl glyceryl ether arachidonylethanolamine esterJournal of Molecular Signaling 2008, 3:5 http://www.jmolecularsignaling.com/content/3/1/5
Page 3 of 19
(page number not for citation purposes)
Various conformations of arachidonyl derivatives in complex with proteins as found within the crystal structures of enzymes  and binding proteins Figure 2
Various conformations of arachidonyl derivatives in complex with proteins as found within the crystal struc-
tures of enzymes and binding proteins. The National Library of Medicine Protein Structure Data Base was searched for 
structures of arachidonic acid and its metabolites and analogs determined from X-ray crystal structures of known enzymes and 
binding proteins. (A) Arachidonic acid in complex with adipocyte lipid binding protein (1ADL), cyclooxygenase active site of 
COX-2 (ICVU), prostaglandin H2 synthase-1 (1DIY), and human serum albumin (1GNJ); (B) Methyl arachidonyl fluorophos-
phonate in complex with fatty acid amide hydrolase (1MT5); (C) 5,8,11,14,17-Eicosapentaenoic acid in complex with peroxi-
some proliferator activated receptor delta (3GWX) and prostaglandin endoperoxide H synthase-1 (1IGX).Journal of Molecular Signaling 2008, 3:5 http://www.jmolecularsignaling.com/content/3/1/5
Page 4 of 19
(page number not for citation purposes)
Table 1: Structures and affinity and relative efficacy data for the conformationally restricted anandamide analogs
Compound Binding affinity, Ki(nM) GTPγS binding Adenylyl cyclase
CP55244 0.11 Strong stimulation Strong inhibition
Anandamide 17 Strong stimulation Strong inhibition
38 Strong stimulation Strong inhibition
59 Moderate stimulation Weak stimulation
305 Moderate stimulation Weak stimulation
335 Strong stimulation Moderate Inhibition
371 Moderate stimulation Weak stimulation
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ands were modelled using two different docking packages:
Glide (Schrödinger, Inc. Portland, OR) and Affinity (Accel-
rys, Inc. San Diego, CA). The working hypothesis was that
these compounds should conform to the same binding
rules as the very potent and stereoselective non-classical
cannabinoid CP55244 [15] (Fig. 1). We describe the
molecular interactions of these novel compounds with
amino acid residues in the binding pocket of the CB1
receptor. The results provide insight into the properties of
the ligand-receptor complex that are associated with affin-
ity and efficacy.
Results
Extracellular loop 2 (E2) conformation of the CB1 receptor
It was revealed from the present CB1 receptor model that
extracellular loop 2 (E2) was located in the central region
of the receptor on the extracellular side and packed at the
entrance of the transmembrane core region (Fig. 3).
Molecular dynamics (MD) simulations showed that con-
formations of E1 and E3 were influenced by the position-
ing of E2 (data not shown), suggesting that the
extracellular loop region can readily adopt protean con-
formational changes in a membrane environment. As
shown in Fig. 3, there were several non-bonding interac-
tions between E1, E2, and E3 that might contribute to
domain stabilization among the extracellular loops. For
example, two H-bonds (R182/Q261 and D184/K259)
between E2 and E1 and one H-bond (D266/K370)
between E2 and E3 were identified. E2 itself was stabilized
not only by the disulfide bridge (C257/C264), but also by
H-bond (E258/K259) and aromatic stacking (W255/
F268) interactions. A closer examination revealed that E2
was stabilized by two well-developed H-bond networks:
1) D184(E1)-K259(E2)-E258(E2)-R186(TM3)-
N256(E2)-P251(TM4); and 2) W255(E2)-D266(E2)-
K370(TM6) (Fig. 3). In addition, there were several H-
bonds between E2 and TM residues, including G254(E2)-
L250(TM4), F268(E2)-D272(TM6), and Q261(E2)-
K376(TM7), which would contribute to the loop stabili-
zation.
Docking of the conformationally restricted anandamide 
analogs by Glide/Prime
As shown in Fig. 4, the CP55244 docking mode deter-
mined by Glide/Prime overlapped quite well with the pre-
viously published CP55244 docking model that had been
developed using Affinity[16]. As described in [16], the
putative binding conformation of CP55244 was identi-
fied and supported by a highly significant correlation
between affinity determined from radioligand binding
studies and ligand-receptor interaction energies for over
30 non-classical cannabinoid agonist ligands. In both
models, the phenolic hydroxyl interacted with K3.28
(192). There was strong aromatic stacking of the A-ring
with F7.35(379) which are 4.7 Å apart. This residue had
contributed the greatest interaction in the previously pub-
lished model [16]. The C3 tail interacts with numerous
residues within TM3 and TM6, as was previously observed
[16].
In its optimum conformation within the binding pocket,
compound 1 occupies the same hydrophobic region of
the receptor as that occupied by the C3 side chain of
CP55244 (Fig. 5A). Compared to the model for CP55244,
the aromatic ring of compound 1 occupies the same loca-
tion as the A-ring of CP55244, but is oriented nearly per-
pendicular to it. The amide side chain occupies the same
location as the C/D fused cyclic region of CP55244, but is
oriented in such a way that the compound 1 terminal
hydroxyl does not overlap with the D-ring hydroxyl of
CP55244. There is potential for aromatic stacking
between the compound 1 aromatic ring and F3.25(189),
which are 6.8 Å apart in this pose. Compound 1 showed
the presence of three hydrogen bonds: the amide NH with
the backbone O of F7.35(379), the carbonyl oxygen of the
amide with the side chain N of K3.28(192), and the termi-
nal hydroxyl with the imidazole ring N of H2.65(178)
(Fig. 5B). Compounds 1 and 2, which differ in the linker
that separates the amide moiety from the aromatic ring,
have the greatest affinity (Ki = 38 nM and 59 nM, respec-
tively) for the receptor (see Table 1). In the best Glide/
Prime pose for compound 2, the benzene ring was perpen-
dicular to the position of the aromatic ring in compound
4960 No change Strong inhibition
Anandamide analogs were selected from a series of compounds developed and tested as reported previously [13]. Binding affinity was determined 
by the ability to compete for [3H]-CP55940 binding in rat brain membranes, G-protein activation was determined by the ability to stimulate [35S]-
GTPγS binding to G-proteins in rat brain membranes, and effector activity was determined by the ability to regulate adenylyl cyclase activity (inhibit 
through Gi or stimulate through Gs) in purified membranes from N18TG2 cells.
Table 1: Structures and affinity and relative efficacy data for the conformationally restricted anandamide analogs (Continued)
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1 as a result of the considerable aromatic stacking with
F2.61(174), F2.64(177) and F3.25(189) (Fig. 5C). Com-
pared with compound 1, compound 2 partially occupied
the hydrophobic pocket and formed H-bonds between
the amide O and the side chain N of K7.32(376) and
between the amide N and the side chain hydroxyl O of
S7.39(383), but no H-bond with K3.28(192). Compound
3 which lacks the methyl group of compound 2, exhibited
limited hydrophobic interaction with neighboring resi-
dues such as I1.35(119) and M7.40(383) (data not
shown). Compound 4, which lacks the methyl group of
compound 1, was raised up toward the extracellular sur-
face compared with the position of the aromatic ring in
compound 1, such that the alkyl tail of 4 could not extend
as deeply into the pocket (data not shown). Comparisons
of the docking of compounds 5 and 6 with 1 indicate that
the ortho-substituted aromatic ring was severely displaced
toward the extracellular surface and TM2 and TM3, and
the heptenyl tail failed to occupy the hydrophobic pocket
(Fig. 5D). The degrees of interaction with the hydropho-
bic pocket for compounds 1, 2, 5 and 6 were estimated by
a root mean square deviation (RMSD) from the corre-
sponding carbons of CP55244. The RMSD for the six tail
carbons were 2.8 Å, 4.8 Å, 4.6 Å and 5.4 Å, respectively.
Extracellular loop placement on the human CB1 receptor model illustrating key interacting residues among E1, E2, and E3 Figure 3
Extracellular loop placement on the human CB1 receptor model illustrating key interacting residues among E1, E2, and E3.Journal of Molecular Signaling 2008, 3:5 http://www.jmolecularsignaling.com/content/3/1/5
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Docking of the conformationally restricted anandamide 
analogs by Affinity/SA
The Affinity/SA model of CP55244 overlaps with the pre-
viously published docking model [15,16], as shown in
Fig. 4 in which the CP55244 phenolic hydroxyl formed an
H-bond with K3.28(192). It is interesting to note that the
C3 side chain in this model pointed toward the hydro-
phobic pocket region between TM3 through TM5 (Fig.
4B). This region is somewhat different from the proposed
hydrophobic pocket for the previously published
CP55244 model, in which the C3 side chain tail pointed
toward the TM core region between TM3 and TM6. The
optimum  Affinity/SA  model of CP55244 shows strong
aromatic interaction with F7.35(379), as shown for the
Glide/Prime  model of CP55244 and for the previously
published CP55244 model [16]. Aromatic stacking inter-
actions exist between the A-ring and F3.25(189), which
are 6.1 Å apart, and between the A-ring and F7.35(379),
which are 5.4 Å apart
As shown in Fig. 6A, the optimum fit of compound 1 is
comparable to that occupied by CP55244, including the
co-localization of the hydrophobic side chains of both
molecules, and the aromatic ring of compound 1 with the
A-ring of CP55244. Compound 1 (Fig. 6B) exhibits a H-
bond between K3.28(192) and the carbonyl of the amide.
The compound 1 terminal hydroxyl occupies the same
location as the D-ring hydroxyl of CP55244. The superpo-
sition model of CP55244 and compound 1 suggests that
the weaker binding affinity of compound 1  compared
with CP55244 could be due to the missing moiety in com-
pound 1 that could correspond to the C/D-ring moiety of
CP55244. There is potential for aromatic stacking
between the compound 1 aromatic ring and F3.25(189)
as well as F7.35(379) as can be seen in the Compound 1
movie (Additional File 1). Compound 2  exhibited a
greater variety of binding modes compared with com-
pound 1. The pose shown in Fig. 6C lacked the H-bonding
interaction with K3.28(192), although the C3 side chain
occupied the same hydrophobic pocket as compound 1
and exhibited energetically favorable aromatic stacking
with F5.42(278), which are 6.7 Å apart. Poses in which
compound  2  exhibited H-bonding with K3.28(192)
showed that the aromatic ring of compound 2 was dis-
placed from the position of the aromatic ring in com-
pound 1 (see Compound 2 movie (Additional File 2)).
Compound 5 occupied an almost identical region as com-
pound 1; in particular, its alkyl tail occupied the same
region. It also exhibited a set of H-bonding interactions
between the aromatic ring OH and K3.28(192), and
Side (A) and top (B) views of the overlay of the docking modes of CP55244 determined using Glide/Prime (in lavender), Affinity/ SA (in cyan) and the previously published CP55244 docking mode (in white) Figure 4
Side (A) and top (B) views of the overlay of the docking modes of CP55244 determined using Glide/Prime (in 
lavender), Affinity/SA (in cyan) and the previously published CP55244 docking mode (in white). The CB1 receptor 
helical backbone is represented in Cα trace format. TM1 through TM7 are colored in red, orange, yellow, green, cyan, blue 
and purple, and the extracellular loops are colored in magenta.
A. side view                   B. top view 
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between the terminal OH and S7.39(383). The aromatic
ring of compound 5, which is 5.5 Å apart from
F7.35(379), was skewed compared with compound 1 due
to the presence of two carbon linker atoms between the
aromatic ring and the amide moiety (not shown). Com-
pound 6 showed H-bonding interactions for the amide
Glide/Prime models of CP55244 compound 1, 2 and 6 Figure 5
Glide/Prime models of CP55244 compound 1, 2 and 6. (A) Overlay of the Glide/Prime models of CP55244 and com-
pound 1. (B) Key amino acid residues of the CB1 receptor for binding with the Glide/Prime model of compound 1. H-bonding 
between compound 1 and the binding pocket residues are represented with white dots. (C) Overlay of the Glide/Prime model 
of compound 2 with compound 1. (D) Overlay of the Glide/Prime model of compound 6 with compound 1.
A.                                                       B. 
C.                                                       D.
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Affinity/SA models of CP55244 and compound 1, 2 and 6 Figure 6
Affinity/SA models of CP55244 and compound 1, 2 and 6. (A) Overlay of the Affinity/SA models of CP55244 and com-
pound 1. (B) Key amino acid residues of the CB1 receptor for binding with the Affinity/SA model of compound 1. H-bonding 
between compound 1 and the binding pocket residues is represented with white dots. (C) Overlay of the Affinity/SA model of 
compound 2 with compound 1. (D) Overlay of the Affinity/SA model of compound 6 with compound 1.
A.                                                       B. 
C.                                                       D.
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and OH terminal with K3.28(192) and S7.39(383), as did
compound 5 (data not shown). However, as a result of the
reduced flexibility imposed by the ortho arrangement of
the moieties on the ring (see below), the heptenyl tail
moiety was severely restricted, thereby limiting interac-
tion with the hydrophobic residues (Fig. 6D) (see Com-
pound  6  movie (Additional File 3)). The RMSD, an
estimate of the degree of interaction with the hydrophobic
pocket, for the six tail carbons of compounds 1, 2, 5 and
6, when compared with CP55244, as were 2.2 Å, 2.7 Å, 0.9
Å and 7.2 Å, respectively.
Linear Interaction Energy (LIE) binding free energy
In order to validate the optimum docking conformations
by a means that would consider the solvation and entropy
effects, we employed the Linear Interaction Energy (LIE)
method based on the Surface Generalized Born contin-
uum solvation model [17]. The experimental ΔGbind val-
ues determined from the binding affinity data were
compared with the estimated ΔGbind values obtained from
the identified docking conformations. Fitting the esti-
mated ΔGbind values from either the Glide/Prime confor-
mations or the Affinity/SA  conformations to their
experimental  ΔGbind  values yielded the following LIE
equations: for the Glide/Prime  conformations,  ΔGbind =
0.381<ΔUvdw> + 0.028 <ΔUelec> + 1.271 ΔSASA; and for
the Affinity/SA conformations, ΔGbind = 0.348 <ΔUvdw> +
0.032 <ΔUelec> + 1.084 ΔSASA. For both conformations,
the RMSD of <1.0 kcal/mol was obtained. Using these
equations, the calculated ΔGbind values correlated well
with the experimental ΔGbind values for compounds 1
through 6 (Fig. 7 and Table 2). The Jackknife correlation
coefficient indicated that the Affinity/SA  conformation
derived LIE equation is more robust than the Glide/Prime
conformation-derived LIE equation (Table 2). However,
these data do not predict efficacy of ligand-induced con-
formational changes that may be required for biological
activity.
Binding energy correlation between experimental ΔGbind and  LIE (Glide/Prime) ΔGbind (A) or LIE (Affinity/SA) ΔGbind (B) Figure 7
Binding energy correlation between experimental ΔGbind and 
LIE (Glide/Prime) ΔGbind (A) or LIE (Affinity/SA) ΔGbind (B).
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Table 2: Binding free energy comparison between the experimental and LIE (Glide/Prime) or LIE (Affinity/SA) values for compounds 1 
through 6
ΔGbind(kcal/mol)
Compound LIE (Glide/Prime)L I E  ( Affinity/SA) Experimental
1 -9.6 -10.1 -10.1
2 -9.9 -9.9 -9.9
3 -9.8 -8.7 -8.9
4 -8.8 -8.7 -8.8
5 -7.5 -8.9 -8.8
6 -7.9 -7.3 -7.2
The Glide/Prime LIE fit was determined using the following equation with a RMSD of 0.6 kcal/mol: ΔGbind = 0.381<ΔUvdw> + 0.028<ΔUelec> + 
1.271ΔSASA. The Affinity/SA LIE fit was determined using the following equation with a RMSD of 0.1 kcal/mol: ΔGbind = 0.348<ΔUvdw> + 
0.032<ΔUelec> + 1.084ΔSASA. The Experimental ΔGbind values were calculated from the experimental Ki values (see Table 1) assumed to be 
equivalent to KD, using ΔGbind = RT ln Ki for T = 298 K.Journal of Molecular Signaling 2008, 3:5 http://www.jmolecularsignaling.com/content/3/1/5
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Table 3: Ligand-receptor non-bonding and H-bonding interactions identified for CP55244 by Affinity and compared with compounds 1, 
2, and 6.
compound nonbonding interaction energy (kcal/mol)
Key Binding Site Residues within 3.5 Å of CP55244 hydrophobic pocket Potential H-bond forming 
residues
F3.25 
(189)
L3.29 
(193)
T3.33 
(197)
P4.60 
(251)
Y5.39 
(275)
F5.42 
(278)
M6.55 
(363)
K3.28 
(192)
S7.39 
(383)
E (258)
CP55244 Coulombic
van der Waals
Total
-0.06
-1.20
-1.26
0.06
-2.21
-2.15
0.02
-0.64
-0.62
0.00
-0.37
-0.37
0.00
-1.20
-1.20
0.00
-0.79
-0.79
0.00
-0.44
-0.44
-0.88
-0.54
-1.41
compound 1
Pose1 Coulombic
van der Waals
Total
0.00
-1.33
-1.33
0.00
-1.64
-1.64
0.00
-0.74
-0.74
0.00
-0.49
-0.49
-0.02
-0.75
-0.77
-1.19
-0.13
-1.32
Pose2 Coulombic
van der Waals
Total
0.01
-1.58
-1.57
0.00
-1.79
-1.79
-0.01
-0.35
-0.36
0.00
-0.46
-0.46
-0.01
-0.45
-0.46
-0.02
-0.74
-0.76
-1.14
-0.59
-1.73
Pose3 Coulombic
van der Waals
Total
-0.01
-2.11
-2.12
0.20
-0.75
-0.55
0.01
-0.45
-0.44
0.09
-1.09
-1.00
0.00
-0.51
-0.51
0.01
-0.78
-0.77
-1.33
-0.74
-2.07
-0.53
-0.83
-1.36
Pose4 Coulombic
van der Waals
Total
-0.02
-1.55
-1.57
0.00
-0.19
-0.19
0.01
-0.57
-0.56
0.01
-0.48
-0.47
0.02
-0.87
-0.85
-1.21
-0.60
-1.81
Pose5 Coulombic
van der Waals
Total
-0.01
-1.32
-1.33
-0.02
-1.85
-1.87
0.00
-0.83
-0.83
0.00
-0.29
-0.29
0.38
-0.90
-0.52
0.00
-0.43
-0.43
-0.02
-1.01
-1.03
-2.39
0.09
-2.30
-0.20
-1.15
-1.35
compound 2
Pose1 Coulombic
van der Waals
Total
-0.02
-1.48
-1.50
0.00
0.02
0.02
0.00
-0.37
-0.37
-0.01
-0.84
-0.85
-1.39
-0.88
-2.26
-0.71
0.06
-0.65
Pose2 Coulombic
van der Waals
Total
0.01
-0.91
-0.90
-0.01
-0.06
-0.07
-0.03
-1.01
-1.04
-0.98
-0.66
-1.64
-0.63
-0.61
-1.24
Pose3 Coulombic
van der Waals
Total
-0.04
-1.67
-1.71
-0.03
-0.75
-0.78
0.00
-0.67
-0.67
-0.02
-1.22
-1.24
-1.33
-0.48
-1.81
Pose4 Coulombic
van der Waals
Total
0.07
-2.85
-2.79
0.00
-0.29
-0.29
0.01
-0.91
-0.90
Pose5 Coulombic
van der Waals
Total
0.05
-0.77
-0.72
0.02
-1.58
-1.56
-0.01
-1.21
-1.22
-1.16
-0.51
-1.67
-0.65
-0.25
-0.90
compound 6
Pose1 Coulombic
van der Waals
Total
-0.01
-0.88
-0.89
-0.02
-1.52
-1.54
0.00
-0.09
-0.09
-0.01
-0.91
-0.92
-2.29
-0.51
-2.80
Pose2 Coulombic
van der Waals
Total
0.01
-1.12
-1.11
-0.04
-1.76
-1.80
-0.01
-0.45
-0.46
0.00
-0.89
-0.89
-2.22
-1.06
-3.28
Pose3 Coulombic
van der Waals
Total
0.04
-0.89
-0.85
0.00
-1.31
-1.31
0.00
-1.04
-1.04
-1.23
-0.55
-1.78
-0.39
-1.41
-1.80
Pose4 Coulombic
van der Waals
Total
0.02
-0.76
-0.74
0.00
-1.39
-1.39
-0.01
-0.77
-0.78
-1.16
-0.47
-1.63
-0.52
-1.23
-1.75
Pose5 Coulombic
van der Waals
Total
0.06
-0.93
-0.87
0.00
-1.36
-1.36
0.00
-0.94
-0.94
-1.06
-0.57
-1.64
-0.46
-0.92
-1.38Journal of Molecular Signaling 2008, 3:5 http://www.jmolecularsignaling.com/content/3/1/5
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Table 3 represents the ligand-receptor interactions within
the hydrophobic pocket that were identified for CP55244
using Affinity/SA (see Fig. 4). Those binding pocket resi-
dues within 3.5 Å of the C3 tail of the ligand were:
F3.25(189), L3.29(193), T3.33(197), P4.60(251),
F5.42(278), and M6.55(363). In addition to these resi-
dues, several residues from E2 and F7.35(379) near the
entrance of the hydrophobic pocket appeared to be close
enough to interact with the C3 tail of the ligand. As shown
in Table 3, of the five different poses tested for compound
1, most showed binding interactions with more than five
of these hydrophobic pocket residues. Compound 2
exhibited three to four such interactions. Compound 6,
the least potent compound tested, showed many fewer
interactions with these residues and smaller interaction
energies. The binding interaction with L3.29(193) was
conserved for all of the ligands, indicating that this bind-
ing interaction might be of particular importance to the
overall binding mode. On the other hand, the binding
interactions with Y5.39(275), F5.42(278) and
M6.55(363) were maintained for all poses of compound
1, but only some poses of compound 2, indicating that
these interactions might be important for the trigger
mechanism of receptor activation [15]. It is interesting to
note that there were additional H-bonding interactions
between the terminal hydroxyl of the ligand and E(258)
or S7.39(383), particularly for compounds 2 and 6. These
H-bonding interactions may distort the conformations of
these compounds thereby reducing the efficacy associated
with activation. These data indicate that the hydrophobic
pocket is crucial for ligand binding, and support the pro-
posal that the degree of interaction with these hydropho-
bic pocket residues is a key determinant in ligand binding
affinity and efficacy.
Aromatic stacking by multiple copy simultaneous search 
(MCSS)
Aromatic stacking appears to be important for the ligand
binding to CB1, as exemplified in all the potent ligand
compounds that contain at least one aromatic ring (i.e.,
the A-ring of cannabinoids, and the indole ring of
WIN55212 and other aminoalkylindole analogs) [18,19].
To further validate the docking position of the benzene
ring in the tested compounds, we explored the best posi-
tion of two key molecular fragments of compound 1 using
the multiple copy simultaneous search (MCSS), a tool
implemented in InsightII  that predicts potential ligand
binding sites. As shown in Fig. 8, the position of the ben-
zene ring nearly overlaps with the aromatic ring of com-
pound 1. The benzene ring in its lowest energy position
was located such that many aromatic residues (including:
F3.25(189), 5.80 Å; F2.61(174), 6.16 Å; F7.35(379), 8.06
Å) were potentially available to contribute to the aro-
matic-aromatic interaction within the binding pocket. The
lowest energy position of the cis-2-butenyl moiety shared
π-π interactions with three aromatic residues: F3.25(189),
Y5.39(275), and F7.35(379), and the cis-2-butenyl moiety
was quite close to the position of the vinyl moiety of com-
pound 1  (Fig. 8). It can be postulated that the lowest
energy position of the cis-2-butenyl moiety would be
equivalent to the hydrophobic pocket that was proposed
to be crucial in cannabinoid binding [18], at least for
those compounds containing the unsaturated hydrocar-
bon side chain for which the π-π interaction would be the
principal interaction [19].
Conformational flexibility explored by MD simulations
In studies to explore the flexibility of the conformation-
ally-restricted anandamide analogs, we examined torsion
angles around the aromatic ring, defined as τ1(C = C-Car-
Car) and τ 2(Car-Car-C = O) during a 5 ns MD simulation
of compounds 1, 2, and 6 (Fig. 9). It was assumed that the
τ 1 torsion angle would indicate the flexibility of the 1-
heptenyl tail of the ligand, while the τ 2 torsion angle
would indicate the flexibility of the polar amide moiety of
the ligand. As shown by the torsion angle of τ 1, com-
pounds 1 and 2 appeared to be quite flexible around the
aromatic ring. In contrast, compound 6 appeared to be
much less flexible as indicated by having only two pre-
dominant orientations, around 120 and -120 degrees,
respectively. The less flexible τ 1 torsion angle of com-
pound 6 would lead to poor binding interaction with the
Comparison of the best position of the benzene and cis-2- butene moieties from MCSS with the Affinity/SA model of  compound 1 Figure 8
Comparison of the best position of the benzene and 
cis-2-butene moieties from MCSS with the Affinity/SA 
model of compound 1. Aromatic residues at or around 
the ligand binding pocket are represented including 
F3.25(189) and F7.35(379) identified as potentially important 
residues for aromatic stacking with compound 1.
2-butene
benzene
Compound 1 
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hydrophobic binding pocket residues. Interestingly, com-
pound 6 showed quite diverse τ 2 torsion angle values,
comparable to those of compounds 1 and 2, suggesting
that the polar amide moiety exhibited great flexibility in
the molecules of this series, and could occupy alternative
positions within the binding pocket.
In Fig. 9, the distance d [(C =)C...O(= C)] between the first
carbon of the 1-heptenyl tail and the amide oxygen was
monitored as the MD simulation progressed. The distance
d [(C =)C...O(= C)] showed quite interesting differences
among compounds 1, 2, and 6. For compound 1, this dis-
tance remained in a very narrow range of values between
5 Å to 6 Å throughout the simulation. As a reference, the
corresponding distance for the best docking conformation
of compound 1 was 5.9 Å, and the distance between the
first carbon of the C3 tail and the A-ring hydroxyl oxygen
of CP55244, as found in the best docking conformation,
Ligand flexibility estimated from MD simulations for compounds 1, 2 and 6 Figure 9
Ligand flexibility estimated from MD simulations for compounds 1, 2 and 6. The torsion angles around the aromatic 
ring, defined as τ 1(C = C-Car-Car) and τ 2(Car-Car-C = O), and the distance between the first carbon atom of the 1-heptenyl 
tail and the amide oxygen atom, defined as d [(C =)C...O(= C)] during a 5 ns MD simulation of compounds 1, 2, and 6. To 
resemble the highly hydrophobic environment within the binding pocket, the dielectric constant ε of 4.0 was used for the elec-
trostatic interaction energy.Journal of Molecular Signaling 2008, 3:5 http://www.jmolecularsignaling.com/content/3/1/5
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was 5.0 Å. Compared with compound 1, compound 2
showed a rather diverse range (4 Å to 8 Å) of the d dis-
tance, suggesting that compound 2 might not be efficient
at occupying both the hydrophobic pocket and maintain-
ing an interaction with K3.28(192) at the same time for
the best conformational changes associated with efficacy.
In contrast, compound 6 showed a narrow range of the
distance d values (3 Å to 4 Å). This restricted distance
might be too limited to satisfy the two important binding
interactions with residues in the hydrophobic pocket as
well as the interaction with K3.28(192).
Discussion
Several CB1 receptor studies support the importance of E2
for cannabinoid ligand binding and efficacy [20-23]. For
many rhodopsin family GPCRs, a disulfide linkage
between Cys residues from TM3 and E2 is important for
maintaining receptor structure and function [24,24-27],
possibly stabilizing coupling between the extracellular
loop and TM core domains [28]. Because the CB1 receptor
lacks such a disulfide linkage, evidence implicates the for-
mation of an alternative disulfide linkage between the two
E2 Cys residues (i.e., C257 and C264) in E2 [20,21]. Our
model suggests that E2 could be further stabilized by a set
of H-bonding networks and other non-bonding interac-
tions with E1, E3 and TM domain residues. A recent muta-
tion study [29] suggests that E1 is indirectly involved in
modulating ligand binding through interaction with the
neighboring E2, and that the negatively charged
D3.20(184) would interact with the K259 residue in E2.
In agreement, our receptor model shows that E1 and E2
interact closely through H-bonding and/or salt bridge for-
mation (R182/Q261 and D184/K259) (Fig. 3). The possi-
bility that K183 in E1 interacts with E258 would be less
convincing due to the following reasons: (1) the K183A
mutation was less detrimental than the D3.20(184)A
mutation in CP55940 binding [29]; and (2) rat and
mouse CB1, in which the E258 residue in E2 is replaced by
a Lys, is incapable of such ionic interaction but still is
comparable to the human CB1  receptor for CP55940
binding [30,31]. One of the H-bonding networks (i.e.,
W255(E2)-D266(E2)-K370 (TM6)), and an aromatic
stacking interaction of W255 and F268, appear to func-
tion as a lock such that E2 is kept in a closed conformation
(see Fig. 3). It can be postulated that as the receptor envi-
ronment changes due to the approaching ligand, this lock
might be disrupted, leading to an open conformation of
E2 with enhanced mobility, together with a transiently
reduced E2 interaction with the neighboring segments.
This would create a space for the incoming ligand to enter
the binding site from the extracellular side.
The effect of solvent was not rigorously considered under
the assumption that E2 would exist as close as possible to
the entrance of the TM core pocket as suggested from the
X-ray structure of rhodopsin [32]. Our models favor the
E2 conformers with increased interactions with the recep-
tor residues for packing. Calculations of MD simulations
in explicit water suggested that inclusion of solvent would
not have much effect on the E2 conformation, inasmuch
as the RMSD was 1.19 Å when compared with the present
receptor model. However, the receptor/membrane envi-
ronment, wherein the membrane polar head groups as
well as the extracellular receptor residues greatly exert
their influence, would be important for precisely deter-
mining the E2 conformation [33].
Assuming that the 1-heptenyl moiety of the structurally-
restricted anandamide analogs would be equivalent to the
1',1'-dimethylheptyl of cannabinol analogs [19,34] and
that the ethanolamide moiety is needed to form H-bond-
ing to K3.28(192), we determined the docking poses of
compounds 1 through 6. At first glance, compounds 1
through 6 look similar in structure in that they commonly
contain a benzene ring, the 1-heptenyl group, and hydrox-
ylamide (see Table 1). However, they significantly differ
conformationally due to the difference in position of the
substituent on the aromatic ring (i.e., ortho-versus meta-)
and the difference in the number of carbon atoms linking
the hydroxylamide moiety to the benzene ring (i.e., the
linker size). Both Glide and Affinity/SA approaches, as any
other docking program, attempt to sample as many ligand
conformations as possible within the predefined binding
pocket. However, due to the enormous conformational
flexibility of the tested compounds, the currently applied
docking methods appear to be limited in properly sam-
pling the conformation space. In Glide, the definition of
the computational search space, based upon defining a
box around the ligand in its initial placement into the
receptor complex, is a fairly conservative approach that
did not generate as wide a sampling of poses as the Affin-
ity/SA  process.  Glide  does not move the protein side
chains, possibly preventing the escape of the ligand from
a local energy minimum. As a result, the poses from Glide
are more predisposed to have a docking conformation
similar to that of CP55244, which was used as a model for
the initial point of the simulation. In an effort to increase
the search space as well as to optimize the conformations,
the poses were run through a sequence of Glide and Prime
steps. The Affinity/SA method permits the opportunity for
the system to overcome local energy traps, and appears to
be better in conformation sampling. Each approach uses
different scoring functions: the Glide score [35] in Glide
versus binding interaction energy in Affinity/SA. One diffi-
culty in scoring docking conformations of the tested com-
pounds derives from the generation of many local energy
minima conformations without substantial energy differ-
ences. Thus, we applied these scoring functions to screen
a set of conformations for each compound for which the
LIE method was applied to select the best docking confor-Journal of Molecular Signaling 2008, 3:5 http://www.jmolecularsignaling.com/content/3/1/5
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mations. The different positions of the K3.28(192) resi-
due and the different hydrophobic pockets determined by
Glide  and  Affinity/SA  exemplifies and emphasizes the
notion of multiple micro-conformational states for the
receptor-ligand complex [36]. With the TM backbone
fixed, the side chains of the binding pocket residues as
well as the extracellular loop residues were allowed to
move freely during the docking simulations. Because the
binding pocket within the TM core is relatively large, it is
possible for the pocket residues to contribute to the mod-
ification of the pocket shape. This is especially true for
hydrophobic residues, which can only be held relatively
fixed when they have close contact for favorable interac-
tions with neighboring hydrophobic residues. In contrast,
polar residues that form very specific H-bonds and/or salt
bridges to other polar residues or the amide backbone
appear to be important for helical packing to stabilize the
receptor framework structure.
In our previous analyses of the steric trigger mechanism of
CB1 receptor conformational changes induced by agonists
[15], the efficacy of non-classical cannabinoid CP55244
was explored by conformational analysis, rotational bar-
rier calculations, and molecular dynamics (MD) simula-
tions. It was demonstrated that the torsion angles of the
C3 side chain showed the most dramatic change when
compared with the ground-state receptor-bound confor-
mation, indicating that rotation around these torsion
angles could be responsible for releasing the ligand strain
energy. We also demonstrated that multiple stages were
involved in the ligand conformational change. We pro-
posed that the C3 side chain serves as the steric trigger,
while the ACD-ring moiety of CP55244 serves as the plug,
and that steric clash with helices within the binding
pocket could induce microconformational adaptation
within the protein. This mechanism would suggest that
rotational flexibility in a ligand may be as important a
determinant of agonist activity as the pharmacophoric
elements that can be identified. Compound 1 exhibits the
best activity of the compounds tested, showing greater
than two-fold increase over basal in [35S]GTPγS binding to
G-proteins and maximal efficacy in the Gi-mediated inhi-
bition of adenylyl cyclase. The anchoring of the amide
moiety by multiple H-bonds as well as the stable position-
ing of the aromatic ring by interactions with hydrophobic
residues constitutes the plug, consistent with a steric trig-
ger mechanism of activation focusing on conformational
mobility of the alkyl chain. This is similar to the C/D-ring
region of CP55244 being anchored, and the dimethylhep-
tyl chain being capable of free rotation around its single
bonds, possibly inducing conformational changes in the
receptor upon rotation [15]. The importance of the ligand
interaction with the receptor through the hydrophobic
tail is exemplified in the receptor binding properties of
CP55940 [37] which exhibited a Ki = 0.137 nM. The ana-
log having no A-ring OH to H-bond with K3.28(192)
exhibited a Ki = 40.2 nM, whereas the analog having no
C3 tail, exhibited a Ki = 441 nM, representing a ten-fold
greater loss of affinity.
Among tested anandamide analogs, compound 2 shows
quite similar binding affinity as anandamide (see Table
1). However, it is striking that compound 2 fails to stimu-
late GTPγS binding or to inhibit adenylyl cyclase activity
(see Table 1). This would be expected of a compound that
either could not form a "plug" or could not contribute a
steric trigger interaction to promote a conformational
change associated with receptor activation. As suggested
from our MD simulation (see Fig. 9B), compound 2 might
not be efficient at occupying both the hydrophobic pocket
and maintaining an interaction with K3.28(192) simulta-
neously. This would reduce the probability of conforma-
tional changes associated with efficacy, rendering the
molecule less likely to trigger a conformational change in
the hydrophobic pocket. In agreement with this observa-
tion, the least potent of the series, compound 6, shows the
least fit to the hydrophobic pocket (Figs. 5 &6). As shown
in the compound 6 movie (Additional File 3), compound
6  does not conform well to the space occupied by
CP55244 and compound 1. It appears that the very poor
binding affinity of compound 6 is due to the lack of inter-
action with the key binding site amino acid residues that
are involved in binding to CP55940 or compound 1. In
agreement, our MD simulation suggested that compound
6 (see Fig. 9C) would fail to exhibit geometry required to
satisfy the two important binding interactions with resi-
dues in the hydrophobic pocket as well as the interaction
with K3.28(192). In addition, an increased conforma-
tional rigidity of the tail of this compound suggests its
reduced efficacy as the steric trigger.
Conclusion
Anandamide can adopt many diverse conformations,
analogous to arachidonic acid which, as a substrate for
proteins, interacts via different bioactive conformations.
Thus, as we identified by two computational methods for
the conformationally-restricted anandamide analogs in
the present study, the docking of anandamide within the
CB1 active site could be presumed to interact in such a way
that includes H-bonding to K3.28(192) and occupancy
within the hydrophobic pocket. The steric trigger mecha-
nism of ligand induction of receptor activation demands
that both a stable "plug" and a movable "trigger" be
secured by receptor-ligand interactions in order to achieve
high efficacy. Due to the absence of either plug or trigger,
compounds having poor efficacy would not be able to
induce a micro-conformational modification in the bind-
ing pocket that could initiate receptor activation.Journal of Molecular Signaling 2008, 3:5 http://www.jmolecularsignaling.com/content/3/1/5
Page 16 of 19
(page number not for citation purposes)
Methods
Computational Methods
All computations and molecular modeling were carried
out on a Silicon Graphics Origin 2000 or Origin 350
workstation.
Construction of the CB1 receptor with the extracellular 
loops incorporated
As the starting structure, the transmembrane helical
domain (TM) of the human CB1 receptor was constructed
using the X-ray structure of rhodopsin (PDB code: 1L9H)
[32] as a template, and the E1 and E3 were constructed by
the random loop search method implemented in InsightII
(version 2000, Accelrys Inc. San Diego, CA). The E2
(G254-W-N-C-E-K-L-Q-S-V-C-S-D-I-F-P269) was
designed with the formation of a disulfide linkage
between the two Cys residues (i.e., C257 and C264) in E2,
as supported by recent studies [20,21]. Assuming the for-
mation of an eight-membered ring through such a
disulfide linkage, the homologous amino acid sequences
to these residues whose structures were determined exper-
imentally were identified from DSDBASE [38]. Among 20
cyclic peptides that showed >70% sequence homology,
those structures were discarded that were from Cys-rich
proteins or exhibited poor geometry to fit into the TM
core. The remaining candidate cyclic peptides were
docked into the extracellular pore region of the CB1 recep-
tor model by using ZDOCK [39,40]. To select a reasonable
position of the peptide at the extracellular side of the TM
core region, the following criteria were considered: 1) the
distance between the Cα of C257 and the Cα of the C-ter-
minal residue of TM4, L4.62(253) was set to be <10 Å
with the presence of the short linking residues (GWN);
and 2) interactions with F3.25(189) were favored because
of evidence that the interaction of this residue with E2 is
critical for CP55940 binding [29]. After determining plau-
sible orientations of the cyclic peptide fragment, the
remaining distal and marginal residues of E2 were intro-
duced by the loop search approach implemented in
InsightII. The simulated annealing (SA) procedure was
then performed with the TM backbones constrained, the
ω angles held to 180 degrees, and the φ and ψ angles of the
residues forming the cyclic peptide fragment held con-
stant at the values from the X-ray structure. The protocol
for SA involved heating to 2,000 K in steps of 100 K over
20 ps, a holding time at 2,000 K for 10 ps, followed by
cooling to 300 K over 34 ps. After holding at 300 K for 10
ps, minimization was performed for 2,500 iterations or
until 0.01 kcal/molÅ energy gradient convergence. The
final minimized conformer was saved and at the same
time used for the next cycle of the SA run. By repeating this
procedure, approximately 1000 conformers were
obtained, which were analyzed by a combination of Pro-
files-3D scores and molecular mechanics energies criteria
[41]. The best CB1 receptor model was selected and used
for the following docking simulations of the rigid ananda-
mide analogs. For energy minimizations and SA simula-
tions, the cell multipole method with a dielectric constant
(ε = 4.0) was used for summation of non-bonding inter-
actions.
Docking of the ligands
Compounds 1 through 6 were docked to the CB1 receptor
using Affinity and Glide. CP55244 was the prototype CB1
receptor agonist used to compare the present receptor
model and verify its correspondence with the previously
published docking model [15,16]. As the starting struc-
tures for docking, we used the lowest energy conformers
of compounds 1 through 6 generated from the SPARTAN
(Version 02, Wavefunction, Inc., Irvine, CA) systematic
search employing MMFF. An initial position of the ligands
within the receptor pocket was guided by the position of
CP55244 determined previously [16]. The docked ligands
were inspected for conformations that fit the following
two selection rules: (1) there would be an interaction with
K3.28(192), which is necessary for high affinity binding
and activity for the classical, non-classical, and endocan-
nabinoid classes of compounds [42,43]; and (2) there
would be occupation of a similar region of the receptor by
the hydrophobic tail of the ligands based on the previ-
ously published structure for CP55244 [15].
i) By Glide/Prime
The receptor complex merged with the ligand was sub-
jected to the protein preparation task in Glide to check for
any incompleteness in the structure. The structure was
processed for the grid generation through Glide, using van
der Waals scaling of the receptor at 0.4 and an electrostatic
constraint to K3.28(192). The default size was used for the
bounding and enclosing boxes. For the ligand docking
stage, van der Waals scaling of the ligand was set at 0.5
and a hydrogen-bond constraint was set to K3.28(192).
Of the 50,000 poses that were sampled, 4,000 were taken
through minimization (conjugate gradients 1,000) and
the 30 structures having the lowest energy conformations
were further evaluated for the presence of a H-bonding
interaction with K3.28(192) and favourable Glide docking
score. The four best discrete structures from Glide that fit
the requirements were each merged with the receptor and
processed through the Prime task for refining the amino
acid side chains. Residues within 10 Å of the ligand were
chosen and the Cα movement was set to zero. The refined
structure was minimized for residues within 7 Å of the lig-
and. This newly optimized structure was used for a second
cycle of Glide docking, using the same grid and run param-
eters. The best structures from each of the four parallel
sequences were compared and the best model structure
for the ligand chosen based on number of hydrogen
bonds, hydrogen bonding to K3.28(192), binding score,
and overall fit to the model for CP55244. This structureJournal of Molecular Signaling 2008, 3:5 http://www.jmolecularsignaling.com/content/3/1/5
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was merged with the receptor and minimized again in
Prime to obtain a final model for the ligand docked within
the CB1 receptor.
This process was initially applied for compound 1, the
most potent ligand tested in the present study (see Table
1) and then repeated for each of the structurally diverse
ligands. Analogs that varied only by the absence of a
methyl group (i.e., compound 1 versus compound 4; and
compound 2 versus compound 3) were docked into the
model of their methylated counterpart using Glide to opti-
mize the conformation of the non-methylated ligand. The
final ligand pose chosen was again processed through
Prime to minimize the complex.
ii) By Affinity/SA
Defining the binding pocket as those residues within 16 Å
of the side chain N of K3.28(192), a combination of
Monte Carlo and SA simulation procedures was employed
to explore docking conformations of the ligands using the
Affinity module in InsightII. During this procedure, the lig-
and and the side chains of the residues within the defined
binding site were allowed to move freely, while other res-
idues were held fixed. The distance between the
K3.28(192) side chain N (as the H-bond donor) and the
carbonyl O (as the H-bond acceptor) of the ligand was
held fixed at 2.1 Å. A set of 100 conformations was
obtained from Monte Carlo sampling and subjected to a
sequence of energy minimizations: (1) minimization
with the TM backbone fixed and the hydrogen bond con-
strained; and (2) minimization without the hydrogen
bond constraint.
The conformation that showed the lowest binding inter-
action energy (ΔEbind) was selected for further sampling by
the SA simulation. The distance between the K3.28(192)
side chain N and the carbonyl O of the ligand was held
fixed at 2.1 Å. The TM backbone was also held fixed, and
only the binding pocket residues within 12 Å of the ini-
tially bound ligand were allowed to freely move. The cis
double bond of the ligand was constrained. The protocol
for SA involved a short MD of 5 ps at 300 K, heating to
1,500 K by an increase of 200 K per ps, a holding time at
1,500 K for 10 ps, followed by cooling to 300 K by a
decrease of 100 K per ps. After holding at 300 K for 5 ps, a
sequence of energy minimizations was performed: (1)
with the H-bonding and the cis double bond constraints;
and (2) without these constraints. The final minimized
conformer was saved and at the same time used for the
next cycle of the SA run. By repeating this procedure,
approximately 100 conformers were obtained. Among the
lowest  ΔEbind conformations, several discrete structures
were selected. This process was applied for compounds 1,
2, 5, and 6 (see Table 1). Ligands that varied only by the
absence of a methyl group (i.e., compounds 3 and 4) were
docked into the model of their methylated counterpart
and minimized.
Binding free energy by the linear interaction energy (LIE) 
method
To determine the most likely binding conformations of
the tested compounds 1 through 6, the candidate confor-
mations of each compound were examined to obtain the
best correlation between their free energy of binding
(ΔGbind) with binding affinity data. The ΔGbind values were
obtained by employing the LIE method [44] implemented
in  Liaison  (Schrödinger, Inc. Portland, OR) using the
OPLS-2003 force field. In the LIE method, ΔGbind =  α
<ΔUvdw> + β < ΔUelec> + γ  ΔSASA, where <ΔUvdw> or
<Uelec> denotes the average change in the van der Waals or
the electrostatic interaction energy of the ligand in the free
and bound states, respectively, and ΔSASA is the change in
the solvent-accessible surface area (SASA). The α, β, and γ
terms are adjustable parameters to fit to experimental
binding free energy data. To briefly describe the method,
a series of hybrid Monte Carlo (HMC) simulations at 300
K were carried out to sample the receptor-ligand complex.
The system was initially heated to 300 K in 5 ps and then
subjected to a MD simulation for 25 ps. A residue-based
cutoff of 12 Å was set for the non-bonding interactions.
The non-bonded pair list was updated every 10 fs. The
time integration step of 1.0 fs and sampling LIE energies
every 10 steps was used. During the MD simulations, all
the residues of the protein beyond 12 Å from the bound
ligand were frozen. Similarly, the average LIE energies for
the ligand were obtained by performing MD simulations
as for the receptor-ligand complex. The SASA term
required for predicting ΔGbind was obtained from the cav-
ity term of the implemented Surface Generalized Born
continuum solvation model [17].
Additional files
For the following movies [Additional files 1, 2 and 3], the
ligand is in ball-and-stick. The CB1 receptor helical back-
bone is represented in Cα trace format, with TM1 through
TM7 colored in red, orange, yellow, green, cyan, blue, and
purple, and the extracellular loops colored in magenta.
Relevant binding site residues, represented in green color
stick, include K3.28(192) (upper left) interacting with the
ethanolamide moiety for the H-bond formation,
Y5.39(275), F5.42(278), and M6.55(363) that represent
the key hydrophobic core residues (lower right) interact-
ing with the heptenyl tail, and F3.25(189) (upper left)
and F7.35(379) (lower left) interacting with the benzene
ring moiety.
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